$OGEN
ORAGENICS INC

2018 Q4 Form 10-Q Financial Statement

#000156459018029292 Filed on November 13, 2018

View on sec.gov

Income Statement

Concept 2018 Q4 2018 Q3 2017 Q3
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.031M $1.184M $930.0K
YoY Change 71.84% 27.29% -15.45%
% of Gross Profit
Research & Development $1.794M $1.581M $996.5K
YoY Change 118.72% 58.61% 7.75%
% of Gross Profit
Depreciation & Amortization $11.72K $8.390K $10.00K
YoY Change -41.4% -16.1% -50.0%
% of Gross Profit
Operating Expenses $2.825M $2.764M $1.922M
YoY Change 99.98% 43.86% -5.19%
Operating Profit -$2.764M -$1.922M
YoY Change 43.86% -5.19%
Interest Expense $68.59K $2.142K $105.9K
YoY Change -237.18% -97.98% 8102.48%
% of Operating Profit
Other Income/Expense, Net $340.00 $6.506K -$145.7K
YoY Change -104.47% -790.67%
Pretax Income -$2.756M -$2.758M -$2.067M
YoY Change 88.74% 33.41% 3.07%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$2.756M -$2.758M -$2.067M
YoY Change 88.65% 33.41% 5.31%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$211.3K -$231.0K -$419.9K
COMMON SHARES
Basic Shares Outstanding 29.43M 11.84M shares 49.27M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2018 Q4 2018 Q3 2017 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $20.21M $13.81M $2.920M
YoY Change 227.53% 372.99% -42.97%
Cash & Equivalents $20.21M $13.81M $2.923M
Short-Term Investments
Other Short-Term Assets $1.725M $1.661M $2.180M
YoY Change 67.47% -23.82% 1182.35%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $21.93M $15.47M $5.101M
YoY Change 204.92% 203.3% -3.54%
LONG-TERM ASSETS
Property, Plant & Equipment $116.3K $63.51K $34.12K
YoY Change 436.85% 86.13% -68.14%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $116.3K $63.51K $34.12K
YoY Change 436.85% 86.13% -68.14%
TOTAL ASSETS
Total Short-Term Assets $21.93M $15.47M $5.101M
Total Long-Term Assets $116.3K $63.51K $34.12K
Total Assets $22.05M $15.54M $5.135M
YoY Change 205.61% 202.53% -4.82%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.043M $1.367M $1.590M
YoY Change 27.24% -14.05% 101.27%
Accrued Expenses $0.00 $0.00
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $124.2K $190.4K $130.0K
YoY Change 55.26% 46.47% 18.18%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $1.168M $1.557M $1.722M
YoY Change 29.94% -9.6% 89.42%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $2.400M
YoY Change -100.0%
Other Long-Term Liabilities $0.00 $0.00
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $2.400M
YoY Change -100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $1.168M $1.557M $1.722M
Total Long-Term Liabilities $0.00 $0.00 $2.400M
Total Liabilities $1.168M $1.557M $4.122M
YoY Change 29.73% -62.23% 353.0%
SHAREHOLDERS EQUITY
Retained Earnings -$111.4M -$108.6M -$99.94M
YoY Change 9.84% 8.68% 8.64%
Common Stock $29.43K $18.42K $49.27K
YoY Change 497.26% -62.62% -99.95%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $20.88M $13.98M $1.013M
YoY Change
Total Liabilities & Shareholders Equity $22.05M $15.54M $5.135M
YoY Change 205.61% 202.53% -4.82%

Cashflow Statement

Concept 2018 Q4 2018 Q3 2017 Q3
OPERATING ACTIVITIES
Net Income -$2.756M -$2.758M -$2.067M
YoY Change 88.65% 33.41% 5.31%
Depreciation, Depletion And Amortization $11.72K $8.390K $10.00K
YoY Change -41.4% -16.1% -50.0%
Cash From Operating Activities -$2.978M -$2.452M -$1.340M
YoY Change 120.59% 82.98% -21.64%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $0.00 $0.00
YoY Change -100.0%
Acquisitions
YoY Change
Other Investing Activities $0.00
YoY Change -100.0%
Cash From Investing Activities $0.00 $0.00 $0.00
YoY Change -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $13.80M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 9.439M 12.39M 2.180M
YoY Change 105.2% 468.23% 129.47%
NET CHANGE
Cash From Operating Activities -2.978M -2.452M -1.340M
Cash From Investing Activities 0.000 0.000 0.000
Cash From Financing Activities 9.439M 12.39M 2.180M
Net Change In Cash 6.461M 9.936M 840.0K
YoY Change 98.81% 1082.8% -354.55%
FREE CASH FLOW
Cash From Operating Activities -$2.978M -$2.452M -$1.340M
Capital Expenditures $0.00 $0.00 $0.00
Free Cash Flow -$2.978M -$2.452M -$1.340M
YoY Change 120.59% 82.98% -20.24%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2018Q3 us-gaap Assets
Assets
15535636
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2018Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
29433135
CY2018Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
13811418
CY2017Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6166143
CY2018Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1660710
CY2017Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1027029
CY2018Q3 us-gaap Assets Current
AssetsCurrent
15472128
CY2017Q4 us-gaap Assets Current
AssetsCurrent
7193172
CY2018Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
63508
CY2017Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
21659
CY2017Q4 us-gaap Assets
Assets
7214831
CY2017Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
818044
CY2017Q4 us-gaap Short Term Non Bank Loans And Notes Payable
ShortTermNonBankLoansAndNotesPayable
80478
CY2018Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
18419135
CY2018Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1580511
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.07
CY2017Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
50000000
CY2018Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2018Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2018Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
18419135
CY2018Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
1366554
CY2018Q3 us-gaap Short Term Non Bank Loans And Notes Payable
ShortTermNonBankLoansAndNotesPayable
190407
CY2018Q3 us-gaap Liabilities Current
LiabilitiesCurrent
1556961
CY2017Q4 us-gaap Liabilities Current
LiabilitiesCurrent
898522
CY2018Q3 us-gaap Preferred Stock Value
PreferredStockValue
6813369
CY2017Q4 us-gaap Preferred Stock Value
PreferredStockValue
6309608
CY2018Q3 us-gaap Common Stock Value
CommonStockValue
18419
CY2017Q4 us-gaap Common Stock Value
CommonStockValue
4928
CY2018Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
115764875
CY2017Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
101402570
CY2018Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-108617988
CY2017Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-101400797
CY2018Q3 us-gaap Stockholders Equity
StockholdersEquity
13978675
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
6316309
CY2018Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
15535636
CY2017Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
7214831
CY2018Q3 us-gaap Preferred Stock No Par Value
PreferredStockNoParValue
CY2017Q4 us-gaap Preferred Stock No Par Value
PreferredStockNoParValue
CY2018Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
50000000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2724349
CY2017Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
925043
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2991300
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2581586
CY2018Q3 us-gaap Operating Expenses
OperatingExpenses
2764341
CY2017Q3 us-gaap Operating Expenses
OperatingExpenses
1921520
us-gaap Operating Expenses
OperatingExpenses
7169594
us-gaap Operating Expenses
OperatingExpenses
5305935
CY2018Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-2764341
CY2017Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-1921520
us-gaap Operating Income Loss
OperatingIncomeLoss
-7169594
us-gaap Operating Income Loss
OperatingIncomeLoss
-5305935
CY2018Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
9066
CY2017Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
3004
us-gaap Investment Income Interest
InvestmentIncomeInterest
15794
us-gaap Investment Income Interest
InvestmentIncomeInterest
6771
CY2018Q3 us-gaap Interest Expense
InterestExpense
2142
CY2017Q3 us-gaap Interest Expense
InterestExpense
105894
us-gaap Interest Expense
InterestExpense
3643
us-gaap Interest Expense
InterestExpense
164560
CY2017Q3 us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
-42918
us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
188726
CY2018Q3 ogen Local Business Tax
LocalBusinessTax
418
us-gaap Restricted Stock Expense
RestrictedStockExpense
114576
us-gaap Stock Option Plan Expense
StockOptionPlanExpense
848612
us-gaap Stock Option Plan Expense
StockOptionPlanExpense
307630
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
6001
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
389191
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
548510
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-6101876
us-gaap Proceeds From Repayments Of Short Term Debt
ProceedsFromRepaymentsOfShortTermDebt
-134561
ogen Net Proceeds From Issuance Of Common Stock And Warrants
NetProceedsFromIssuanceOfCommonStockAndWarrants
1510327
ogen Par Value Of Common Stock Issued
ParValueOfCommonStockIssued
13
CY2017Q3 ogen Local Business Tax
LocalBusinessTax
588
ogen Local Business Tax
LocalBusinessTax
1078
ogen Local Business Tax
LocalBusinessTax
2988
CY2017Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
4927422
CY2017Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
686
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
7194
CY2018Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
6506
CY2017Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-145710
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
11073
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
35143
CY2018Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-2757835
CY2017Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-2067230
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-7158521
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-5270792
CY2018Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2017Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2018Q3 us-gaap Net Income Loss
NetIncomeLoss
-2757835
CY2017Q3 us-gaap Net Income Loss
NetIncomeLoss
-2067230
us-gaap Net Income Loss
NetIncomeLoss
-7158521
us-gaap Net Income Loss
NetIncomeLoss
-5270792
CY2018Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-4169876
CY2017Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-2067230
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-8570562
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-5270792
CY2018Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.35
CY2017Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.42
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.12
CY2018Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
11937624
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
7656670
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
4924667
us-gaap Depreciation And Amortization
DepreciationAndAmortization
18393
us-gaap Depreciation And Amortization
DepreciationAndAmortization
53342
us-gaap Restricted Stock Expense
RestrictedStockExpense
24320
us-gaap Adjustment Of Warrants Granted For Services
AdjustmentOfWarrantsGrantedForServices
118237
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
456496
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
317179
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-5005050
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
60242
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-60242
us-gaap Proceeds From Repayments Of Short Term Debt
ProceedsFromRepaymentsOfShortTermDebt
-110354
ogen Net Proceeds From Issuance Of Common Stock Convertible Preferred Stock And Warrants
NetProceedsFromIssuanceOfCommonStockConvertiblePreferredStockAndWarrants
12431627
us-gaap Proceeds From Issuance Of Preferred Stock Preference Stock And Warrants
ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants
2935792
us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
2400000
ogen Proceeds From Payment Of Stock Subscription Receivable
ProceedsFromPaymentOfStockSubscriptionReceivable
30563
us-gaap Proceeds From Repayments Of Restricted Cash Financing Activities
ProceedsFromRepaymentsOfRestrictedCashFinancingActivities
-1408115
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
13807393
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
3847886
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
7645275
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-1157164
CY2016Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
4080618
CY2017Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2923454
us-gaap Interest Paid Net
InterestPaidNet
3643
us-gaap Interest Paid Net
InterestPaidNet
3040
us-gaap Notes Assumed1
NotesAssumed1
244490
us-gaap Notes Assumed1
NotesAssumed1
172047
ogen Par Value Of Restricted Shares Issued
ParValueOfRestrictedSharesIssued
16
ogen Par Value Of Restricted Shares Issued
ParValueOfRestrictedSharesIssued
160
CY2018Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
4900000
CY2018Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
45000000
CY2018Q2 us-gaap Sale Of Stock Price Per Share
SaleOfStockPricePerShare
0.001
CY2018Q2 ogen Class Of Warrant Granted In Period Exercise Price
ClassOfWarrantGrantedInPeriodExercisePrice
2.00
CY2018Q3 ogen Proceeds From Issuance Public Offering Excluding Proceeds From Exercise Of Warrants
ProceedsFromIssuancePublicOfferingExcludingProceedsFromExerciseOfWarrants
12400000
ogen Fair Market Value Of Warrants Issued
FairMarketValueOfWarrantsIssued
118237
CY2017Q2 ogen Number Of Accredited Investors
NumberOfAccreditedInvestors
3
ogen Class Of Warrants Granted For Financial Advisory Services
ClassOfWarrantsGrantedForFinancialAdvisoryServices
483870
CY2018Q3 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
13800000
CY2018Q3 ogen Beneficial Ownership Limitation Percentage
BeneficialOwnershipLimitationPercentage
0.0499
us-gaap Nature Of Operations
NatureOfOperations
<div> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1. Organization</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Oragenics, Inc. (formerly known as Oragen, Inc.) (the &#8220;Company&#8221; or &#8220;we&#8221;) was incorporated in November, 1996; however, operating activity did not commence until 1999. We are focused on becoming a leader in developing novel antibiotics against infectious disease and on developing effective treatments for oral mucositis.</p></div>
us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with US&#160;GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of expenses during the reporting period. Actual results could differ from those estimates. The principal areas of estimation reflected in the financial statements are anticipated milestone payments, stock based compensation, valuation of warrants, accounting for clinical trial costs, and income tax valuation allowance. </p></div>
CY2018Q3 ogen Ownership Percentage Notification Period Requirement
OwnershipPercentageNotificationPeriodRequirement
P61D
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Concentrations</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments which potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents. The Company maintains cash accounts in commercial banks, which may, at times, exceed federally insured limits. The Company has not experienced any losses in such accounts. The Company believes it is not exposed to any significant credit risk on cash and cash equivalents. As of September&#160;30, 2018, the uninsured portion of this balance was $13,561,418. As of December&#160;31, 2017, the uninsured portion of this balance was $5,916,143.</p></div>
CY2018Q1 ogen Fractional Shares From Reverse Stock Split Share
FractionalSharesFromReverseStockSplitShare
0
us-gaap Revenues
Revenues
0
CY2018Q3 us-gaap Cash Uninsured Amount
CashUninsuredAmount
13561418
CY2017Q4 us-gaap Cash Uninsured Amount
CashUninsuredAmount
5916143
CY2018Q3 us-gaap Share Based Compensation
ShareBasedCompensation
648302
CY2017Q3 us-gaap Share Based Compensation
ShareBasedCompensation
127440
us-gaap Share Based Compensation
ShareBasedCompensation
872932
us-gaap Share Based Compensation
ShareBasedCompensation
422206
CY2018Q3 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
1813633
CY2018Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
195617
CY2018Q3 ogen Class Of Warrant Granted In Period
ClassOfWarrantGrantedInPeriod
13800000
CY2018Q3 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
13800000
CY2018Q2 ogen Class Of Warrant Granted In Period
ClassOfWarrantGrantedInPeriod
900000
CY2018Q2 ogen Common Stock Offering Price Per Share
CommonStockOfferingPricePerShare
2.00
CY2018Q2 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
900000
CY2018Q2 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
2.00
CY2018Q2 ogen Class Of Warrant Or Right Exercisable Period
ClassOfWarrantOrRightExercisablePeriod
P6M
CY2018Q2 ogen Class Of Warrant Or Right Term
ClassOfWarrantOrRightTerm
P5Y
CY2016Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
17559
CY2017 ogen Class Of Warrant Granted In Period
ClassOfWarrantGrantedInPeriod
2177425
CY2017 ogen Class Of Warrant Exercised
ClassOfWarrantExercised
0
CY2017 ogen Class Of Warrant Expired
ClassOfWarrantExpired
17559
CY2017Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
2177425
ogen Class Of Warrant Granted In Period
ClassOfWarrantGrantedInPeriod
14700000
ogen Class Of Warrant Exercised
ClassOfWarrantExercised
0
CY2018Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
16877425
CY2017Q1 us-gaap Capital Units Authorized
CapitalUnitsAuthorized
120000000
CY2017Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2018Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2018Q1 ogen Stock Holders Equity Reverse Stock Split Conversion Ratio
StockHoldersEquityReverseStockSplitConversionRatio
0.1
CY2018Q1 ogen Stockholders Equity Reverse Stock Split Effective Date
StockholdersEquityReverseStockSplitEffectiveDate
2018-01-19
CY2018Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
45000000

Files In Submission

Name View Source Status
0001564590-18-029292-index-headers.html Edgar Link pending
0001564590-18-029292-index.html Edgar Link pending
0001564590-18-029292.txt Edgar Link pending
0001564590-18-029292-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
ogen-10q_20180930.htm Edgar Link pending
ogen-20180930.xml Edgar Link completed
ogen-20180930.xsd Edgar Link pending
ogen-20180930_cal.xml Edgar Link unprocessable
ogen-20180930_def.xml Edgar Link unprocessable
ogen-20180930_lab.xml Edgar Link unprocessable
ogen-20180930_pre.xml Edgar Link unprocessable
ogen-ex311_354.htm Edgar Link pending
ogen-ex312_353.htm Edgar Link pending
ogen-ex321_352.htm Edgar Link pending
ogen-ex322_351.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending